Protocol Ledger

NCT06924606 · Phase II · TERMINATED

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

Interventional Phase II clinical trial protocol NCT06924606 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-15 Enrollment: 18 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06924606
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06924606
Protocol FieldVerified Registry Value
NCT IdentifierNCT06924606
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment18 participants (ACTUAL)
Registered Start Date2025-07-15
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06924606
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaOpen Hospital Dossier ->
Shanghai Pulmonary HospitalShanghai, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI